AbCellera Biologics Inc.
NASDAQ:ABCL
2.31 (USD) • At close June 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4.235 | 5.05 | 6.507 | 7.323 | 9.954 | 9.179 | 6.599 | 10.056 | 12.192 | 21.545 | 101.383 | 45.917 | 316.581 | 139.331 | 5.508 | 27.643 | 202.741 | 207.908 | 9.362 | 11.228 | 4.657 | 3.202 | 3.451 | 2.479 | 2.479 |
| Cost of Revenue
| 42.496 | 13.901 | 38.295 | 38.037 | 6.766 | 9.109 | 7.409 | 7.256 | 52.647 | 1.554 | 15.035 | 5.21 | 44.637 | 21.894 | 17.45 | 3.61 | 20.01 | 35.779 | 7.495 | 9.144 | 4.118 | 3.309 | 2.782 | 2.011 | 2.011 |
| Gross Profit
| -38.261 | -8.851 | -31.788 | -30.714 | 3.188 | 0.07 | -0.81 | 2.8 | -40.455 | 19.991 | 86.348 | 40.707 | 271.944 | 117.437 | -11.942 | 24.033 | 182.731 | 172.129 | 1.867 | 2.084 | 0.539 | -0.106 | 0.669 | 0.468 | 0.468 |
| Gross Profit Ratio
| -9.034 | -1.753 | -4.885 | -4.194 | 0.32 | 0.008 | -0.123 | 0.278 | -3.318 | 0.928 | 0.852 | 0.887 | 0.859 | 0.843 | -2.168 | 0.869 | 0.901 | 0.828 | 0.199 | 0.186 | 0.116 | -0.033 | 0.194 | 0.189 | 0.189 |
| Reseach & Development Expenses
| 42.496 | 46.076 | 40.969 | 40.927 | 39.287 | 48.622 | 37.917 | 36.473 | 52.647 | 28.245 | 26.582 | 26.685 | 26.366 | 17.209 | 17.45 | 15.046 | 12.352 | 8.636 | 7.495 | 9.144 | 4.118 | 3.309 | 2.782 | 2.011 | 2.011 |
| General & Administrative Expenses
| 16.226 | 16.02 | 19.147 | 20.192 | 17.352 | 15.974 | 14.369 | 15.521 | 15.134 | 13.015 | 13.792 | 14.412 | 14.268 | 12.89 | 11.271 | 11.203 | 6.422 | 5.794 | 2.968 | 1.498 | 1.65 | 0.975 | 0.703 | 0.535 | 0.535 |
| Selling & Marketing Expenses
| 2.842 | 3.144 | 3.135 | 3.136 | 3.365 | 3.1 | 3.468 | 3.841 | 3.771 | 2.691 | 3.089 | 3.12 | 2.37 | 1.827 | 1.217 | 1.295 | 2.578 | 2.232 | 0.626 | 0.547 | 0.437 | 0.471 | 0.291 | 0.25 | 0.25 |
| SG&A
| 19.068 | 19.164 | 22.282 | 21.813 | 18.795 | 19.074 | 17.837 | 19.362 | 18.905 | 15.706 | 16.881 | 17.532 | 16.638 | 14.717 | 12.488 | 12.498 | 9 | 8.026 | 3.594 | 2.045 | 2.087 | 1.446 | 0.994 | 0.786 | 0.786 |
| Other Expenses
| 5.331 | 12.565 | 36.919 | 32.156 | -1.529 | 3.106 | 2.046 | -1.97 | 2.14 | 13.818 | 3 | 3.351 | -1.204 | -1.354 | -1.256 | 0.314 | 0.265 | 5.226 | -2.262 | -0.293 | -1.001 | -0.111 | 0 | 0 | 0 |
| Operating Expenses
| 66.895 | 77.805 | 100.17 | 62.74 | 58.082 | 71.856 | 58.661 | 56.869 | 73.692 | 57.769 | 46.463 | 47.568 | 41.8 | 30.572 | 29.224 | 26.42 | 21.509 | 21.888 | 9.793 | 4.232 | 5.749 | 4.643 | 0.626 | 0.766 | 0.766 |
| Operating Income
| -105.156 | -72.755 | -93.663 | -93.454 | -54.894 | -66.053 | -54.89 | -51.389 | -61.5 | -37.778 | 37.735 | -6.861 | 224.95 | 81.553 | -28.096 | -7.033 | 158.074 | 160.774 | -1.768 | -0.854 | -2.122 | -1.976 | -0.716 | -0.713 | -0.713 |
| Operating Income Ratio
| -24.83 | -14.407 | -14.394 | -12.762 | -5.515 | -7.196 | -8.318 | -5.11 | -5.044 | -1.753 | 0.372 | -0.149 | 0.711 | 0.585 | -5.101 | -0.254 | 0.78 | 0.773 | -0.189 | -0.076 | -0.456 | -0.617 | -0.207 | -0.287 | -0.287 |
| Total Other Income Expenses Net
| 52.172 | 25.926 | 31.031 | 45.267 | 12.147 | 17.451 | 15.614 | 13.385 | 16.726 | 6.366 | 8.852 | 1.51 | 5.859 | 3.157 | 3.124 | 4.96 | 3.413 | -4.86 | -0.925 | 7.557 | 0.029 | 0.335 | 0.752 | 0.41 | 0.41 |
| Income Before Tax
| -52.984 | -46.829 | -62.632 | -48.187 | -42.747 | -48.602 | -39.276 | -38.004 | -48.148 | -31.412 | 46.587 | -6.886 | 230.809 | 84.71 | -24.972 | -2.073 | 161.487 | 155.915 | -2.693 | 6.703 | -2.093 | -1.641 | 0.036 | -0.303 | -0.303 |
| Income Before Tax Ratio
| -12.511 | -9.273 | -9.625 | -6.58 | -4.294 | -5.295 | -5.952 | -3.779 | -3.949 | -1.458 | 0.46 | -0.15 | 0.729 | 0.608 | -4.534 | -0.075 | 0.797 | 0.75 | -0.288 | 0.597 | -0.449 | -0.512 | 0.01 | -0.122 | -0.122 |
| Income Tax Expense
| -7.363 | -12.619 | -11.525 | -11.257 | -2.137 | -1.452 | -10.666 | -7.476 | -8.038 | -1.519 | 19.963 | -0.101 | 62.236 | 24.762 | -3.592 | 0.25 | 44.266 | 0.039 | 0 | 0 | 0 | 0.082 | 0 | 0 | 0 |
| Net Income
| -45.621 | -34.21 | -51.107 | -36.93 | -40.61 | -47.15 | -28.61 | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 | 168.573 | 59.948 | -21.38 | -2.323 | 117.221 | 117 | -2.693 | 6.703 | -2.093 | -1.641 | 0.036 | -0.303 | -0.303 |
| Net Income Ratio
| -10.772 | -6.774 | -7.854 | -5.043 | -4.08 | -5.137 | -4.336 | -3.036 | -3.29 | -1.387 | 0.263 | -0.148 | 0.532 | 0.43 | -3.882 | -0.084 | 0.578 | 0.563 | -0.288 | 0.597 | -0.449 | -0.512 | 0.01 | -0.122 | -0.122 |
| EPS
| -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.099 | -0.11 | -0.14 | -0.1 | 0.084 | -0.024 | 0.54 | 0.21 | -0.08 | -0.009 | 0.43 | 0.43 | -0.01 | 0.031 | -0.01 | -0.008 | 0 | -0.002 | -0.002 |
| EPS Diluted
| -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.099 | -0.11 | -0.14 | -0.099 | 0.084 | -0.024 | 0.54 | 0.21 | -0.077 | -0.009 | 0.37 | 0.37 | -0.01 | 0.028 | -0.009 | -0.007 | 0 | -0.002 | -0.002 |
| EBITDA
| -39.602 | -55.311 | -51.877 | -56.932 | -48.128 | -58.517 | -44.653 | -39.557 | -59.36 | -4.664 | 53.315 | -0.845 | 235.782 | 94.798 | -20.766 | 2.142 | 165.453 | 162.304 | 0.506 | 8.076 | -0.446 | -1.061 | -0.326 | -0.318 | -0.318 |
| EBITDA Ratio
| -9.351 | -10.953 | -7.972 | -7.774 | -4.835 | -6.375 | -6.767 | -3.934 | -4.869 | -0.216 | 0.526 | -0.018 | 0.745 | 0.68 | -3.77 | 0.077 | 0.816 | 0.781 | 0.054 | 0.719 | -0.096 | -0.331 | -0.094 | -0.128 | -0.128 |